Epilepsy and Cranial nerve affection in a Patient with Wilson’s disease and Intracranial developmental venous anomaly; A Case Report
Objective: 1.present unusual and rare clinical presentations in the disease spectrum2.study Intracranial developmental venous anomalies (DVAs) presentations both clinically and radiologically in Wilson’s disease and their…Vitamin D and Clinical Phenotypes of Parkinson’s Disease
Objective: To explore the relationship of clinical phenotypes of Parkinson's disease (PD) with vitamin D levels in Veterans diagnosed with PD. Background: PD is a heterogeneous neurodegenerative…Preventing Levodopa Induced Dyskinesia with Docosohexanoid Acid in Parkinson Disease
Objective: The purpose of this study was to determine if Docosohexanoic acid (DHA) affects the speed and severity of development of levodopa induced dyskinesia (LID) in subjects starting levodopa (LD).…How will new technology change deep brain stimulation programming?
Objective: Assess the ways in which decision support tools and directional leads are affecting DBS programming. Background: The typical approach to DBS programming has changed…A prospective comparison of apomorphine, STN deep brain stimulation and levodopa-carbidopa intestinal gel therapy for motor fluctuations in PD
Objective: To compare the clinical, functional and quality of life (QoL) outcomes in patients with advanced Parkinson’s disease (PD) following treatment with apomorphine (APO), either…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…Post-hoc analyses of the recommended starting dose for Rytary based on “off” time
Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…Decision-making process for opicapone’s bedtime regimen
Objective: To clarify the decision-making process for opicapone’s bedtime regímen. Background: OPC, a new once-daily COMT inhibitor, was shown to be effective in the treatment…Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation
Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…Evaluation of Brainstem Auditory Evoked Response and Nerve Conduction in Parkinson’s Disease
Objective: The Aim of our study was to evaluate Nerve Conduction Velocity & Brainstem Auditory Evoked Response in patients with Parkinson’s disease. Background: Parkinson’s disease is a progressive…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 155
- Next Page »